Jesus B Mantas - Net Worth and Insider Trading

Jesus B Mantas Net Worth

The estimated net worth of Jesus B Mantas is at least $878,956 dollars as of 2023-05-29. Jesus B Mantas is the Director of Biogen Inc and owns about 2,943 shares of Biogen Inc (BIIB) stock worth over $878,956. Details can be seen in Jesus B Mantas's Latest Holdings Summary section.

Transaction Summary of Jesus B Mantas


Jesus B Mantas Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jesus B Mantas owns 1 companies in total, including Biogen Inc (BIIB) .

Click here to see the complete history of Jesus B Mantas’s form 4 insider trades.

Insider Ownership Summary of Jesus B Mantas

Ticker Comapny Transaction Date Type of Owner
BIIB Biogen Inc 2019-06-19 director

Jesus B Mantas Latest Holdings Summary

Jesus B Mantas currently owns a total of 1 stock. Jesus B Mantas owns 2,943 shares of Biogen Inc (BIIB) as of February 9, 2021, with a value of $878,956.

Latest Holdings of Jesus B Mantas

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
BIIB Biogen Inc 2021-02-09 2,943 298.66 878,956

Holding Weightings of Jesus B Mantas

Jesus B Mantas Form 4 Trading Tracker

According to the SEC Form 4 filings, Jesus B Mantas has made a total of 1 transactions in Biogen Inc (BIIB) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Biogen Inc is the acquisition of 898 shares on February 9, 2021, which cost Jesus B Mantas around $239,766.

Insider Trading History of Jesus B Mantas

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jesus B Mantas Trading Performance

GuruFocus tracks the stock performance after each of Jesus B Mantas's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jesus B Mantas is 1.76%. GuruFocus also compares Jesus B Mantas's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jesus B Mantas within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jesus B Mantas's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jesus B Mantas

Average Relative Return

Outperforming Transactions

Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Relative Return(%) -1.05 1.76 26.32 -15.78 3.23
Relative Return to S&P 500(%) -0.13 -6.46 13 -33.06 1.08

Jesus B Mantas Ownership Network

Ownership Network List of Jesus B Mantas

No Data

Ownership Network Relation of Jesus B Mantas

Jesus B Mantas Owned Company Details

What does Biogen Inc do?

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021, followed by Leqembi in January 2023.

Who are the key executives at Biogen Inc?

Jesus B Mantas is the director of Biogen Inc. Other key executives at Biogen Inc include Head of Corporate Development Adam Keeney , Head of Development Priya Singhal , and director & President and CEO Christopher Viehbacher .

Biogen Inc (BIIB) Insider Trades Summary

Over the past 18 months, Jesus B Mantas made no insider transaction in Biogen Inc (BIIB). Other recent insider transactions involving Biogen Inc (BIIB) include a net sale of 8,291 shares made by Ginger Gregory , a net sale of 659 shares made by Priya Singhal , and a net sale of 5,532 shares made by Susan H Alexander .

In summary, during the past 3 months, insiders sold 3,340 shares of Biogen Inc (BIIB) in total and bought 0 shares, with a net sale of 3,340 shares. During the past 18 months, 14,482 shares of Biogen Inc (BIIB) were sold and 0 shares were bought by its insiders, resulting in a net sale of 14,482 shares.

Biogen Inc (BIIB)'s detailed insider trading history can be found in Insider Trading Tracker table.


Biogen Inc Insider Transactions

No Available Data

Jesus B Mantas Mailing Address

Above is the net worth, insider trading, and ownership report for Jesus B Mantas. You might contact Jesus B Mantas via mailing address: Biogen Inc., 225 Binney Street, Cambridge Ma 02142.